6533b7d1fe1ef96bd125d980
RESEARCH PRODUCT
Profiles of Volatile Biomarkers Detect Tuberculosis from Skin
Rotem VishinkinRami BusoolHossam HaickGirts SkendersMarcis LejaSarman SinghParveen KumarFalk FishAli EsmailKeertan DhedaKeertan DhedaJohn C. CancillaJosé S. TorrecillaAlaa GharaaElias Mansoursubject
Malepoint‐of‐care testdiagnosisGeneral Chemical EngineeringGeneral Physics and AstronomyMedicine (miscellaneous)02 engineering and technology01 natural sciencesSouth AfricasensorGeneral Materials ScienceResearch ArticlesQGeneral EngineeringClinical performanceMiddle Aged021001 nanoscience & nanotechnologytuberculosisFemale0210 nano-technologyPulmonary tbResearch ArticleAdultmedicine.medical_specialtyskinTuberculosisPoint-of-care testingScienceIndiawearable device010402 general chemistrySensitivity and SpecificityBiochemistry Genetics and Molecular Biology (miscellaneous)Gas Chromatography-Mass SpectrometryWorld healthYoung AdultmedicineHumansIntensive care medicineVolatile Organic Compoundsbusiness.industrynoninvasive approachReproducibility of Resultsmedicine.diseaseTriage0104 chemical sciencesInfectious disease (medical specialty)Test requirementsbusinessBiomarkersdescription
Abstract Tuberculosis (TB) is an infectious disease that threatens >10 million people annually. Despite advances in TB diagnostics, patients continue to receive an insufficient diagnosis as TB symptoms are not specific. Many existing biodiagnostic tests are slow, have low clinical performance, and can be unsuitable for resource‐limited settings. According to the World Health Organization (WHO), a rapid, sputum‐free, and cost‐effective triage test for real‐time detection of TB is urgently needed. This article reports on a new diagnostic pathway enabling a noninvasive, fast, and highly accurate way of detecting TB. The approach relies on TB‐specific volatile organic compounds (VOCs) that are detected and quantified from the skin headspace. A specifically designed nanomaterial‐based sensors array translates these findings into a point‐of‐care diagnosis by discriminating between active pulmonary TB patients and controls with sensitivity above 90%. This fulfills the WHO's triage test requirements and poses the potential to become a TB triage test.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-08-01 | Advanced Science |